KeyCorp Issues Pessimistic Forecast for Certara (NASDAQ:CERT) Stock Price

Certara (NASDAQ:CERT) had its price objective dropped by equities researchers at KeyCorp from $13.00 to $12.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. KeyCorp’s price objective would suggest a potential upside of 26.34% from the company’s previous close.

A number of other research firms have also weighed in on CERT. Stephens cut their price objective on Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday, December 12th. Craig Hallum started coverage on Certara in a report on Monday, September 29th. They set a “buy” rating and a $16.00 price target on the stock. Rothschild Redb raised Certara to a “strong-buy” rating in a research report on Friday, November 21st. Barclays lowered their price objective on Certara from $14.00 to $13.00 and set an “overweight” rating for the company in a research report on Monday, December 15th. Finally, Leerink Partners upgraded shares of Certara from a “market perform” rating to an “outperform” rating and set a $13.00 target price on the stock in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Certara currently has an average rating of “Moderate Buy” and an average price target of $12.58.

Certara Trading Down 0.8%

Shares of CERT stock opened at $9.50 on Thursday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09. The firm has a market capitalization of $1.51 billion, a P/E ratio of 135.57 and a beta of 1.46. The stock’s fifty day moving average is $9.19 and its two-hundred day moving average is $10.57. Certara has a fifty-two week low of $8.02 and a fifty-two week high of $15.69.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. Certara had a net margin of 2.62% and a return on equity of 5.18%. The business had revenue of $104.62 million during the quarter, compared to analyst estimates of $104.53 million. During the same quarter last year, the firm posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. Research analysts expect that Certara will post 0.28 earnings per share for the current fiscal year.

Institutional Trading of Certara

Institutional investors have recently modified their holdings of the stock. Associated Banc Corp boosted its holdings in shares of Certara by 9.7% in the 3rd quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after buying an additional 1,051 shares in the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in Certara by 2.5% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock valued at $535,000 after acquiring an additional 1,136 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock worth $35,000 after purchasing an additional 1,153 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after purchasing an additional 1,175 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd lifted its holdings in shares of Certara by 22.5% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 6,665 shares of the company’s stock valued at $78,000 after purchasing an additional 1,223 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.